{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:03:06Z","timestamp":1770825786857,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00120-025-02761-9","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:03:29Z","timestamp":1769497409000},"page":"133-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Wie l\u00e4sst sich die Eignung eines geriatrischen Patienten f\u00fcr eine uroonkologische Therapie erkennen?","How can the suitability of a\u00a0geriatric patient for uro-oncological treatment be determined?"],"prefix":"10.1007","volume":"65","author":[{"given":"A.","family":"Wiedemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Manseck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kirschner-Hermanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bannowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wirz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. H.","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"2761_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000244903","volume":"7","author":"B Isaacs","year":"1965","unstructured":"Isaacs\u00a0B (1965) Prognostic factors in elderly patients in a\u00a0geriatric institution. Gerontol Clin 7:202\u2013215","journal-title":"Gerontol. Clin."},{"key":"2761_CR2","first-page":"627","volume":"113","author":"D Mosshammer","year":"2016","unstructured":"Mosshammer\u00a0D, Haumann\u00a0H, Morike\u00a0K, Joos\u00a0S (2016) Polypharmacy-an upward trend with unpredictable effects. Dtsch \u00c4rztebl Int 113:627\u2013633","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2761_CR3","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2022.0377","author":"NK Mann","year":"2023","unstructured":"Mann\u00a0NK, Mathes\u00a0T, Sonnichsen\u00a0A et\u00a0al (2023) Potentially inadequate medications in the elderly: PRISCUS\u00a02.0-first update of the PRISCUS list. Dtsch \u00c4rztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2022.0377","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2761_CR4","doi-asserted-by":"publisher","DOI":"10.1055\/a-0736-3722","author":"A Wiedemann","year":"2018","unstructured":"Wiedemann\u00a0A, Puttmann\u00a0J, Heppner\u00a0H (2018) The ISAR-positive patient in urology. Aktuelle Urol. https:\/\/doi.org\/10.1055\/a-0736-3722","journal-title":"Aktuelle Urol"},{"key":"2761_CR5","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1001\/archinte.1991.00400090107019","volume":"151","author":"MH Beers","year":"1991","unstructured":"Beers\u00a0MH, Ouslander\u00a0JG, Rollingher\u00a0I, Reuben\u00a0DB, Brooks\u00a0J, Beck\u00a0JC (1991) Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 151:1825\u20131832","journal-title":"Arch Intern Med"},{"key":"2761_CR6","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1001\/archinte.163.22.2716","volume":"163","author":"DM Fick","year":"2003","unstructured":"Fick\u00a0DM, Cooper\u00a0JW, Wade\u00a0WE, Waller\u00a0JL, Maclean\u00a0JR, Beers\u00a0MH (2003) Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a\u00a0US consensus panel of experts. Arch Intern Med 163:2716\u20132724","journal-title":"Arch Intern Med"},{"key":"2761_CR7","first-page":"543","volume":"107","author":"S Holt","year":"2010","unstructured":"Holt\u00a0S, Schmiedl\u00a0S, Thurmann\u00a0PA (2010) Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch \u00c4rztebl Int 107:543\u2013551","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2761_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40266-016-0371-4","volume":"33","author":"F Pazan","year":"2016","unstructured":"Pazan\u00a0F, Weiss\u00a0C, Wehling\u00a0M, Forta (2016) The FORTA (Fit fOR The Aged) list 2015: update of a\u00a0validated clinical tool for improved pharmacotherapy in the elderly. Drugs Aging 33:447\u2013449","journal-title":"Drugs Aging"},{"key":"2761_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40266-013-0146-0","volume":"31","author":"AM Kuhn-Thiel","year":"2014","unstructured":"Kuhn-Thiel\u00a0AM, Weiss\u00a0C, Wehling\u00a0M (2014) Consensus validation of the FORTA (Fit fOR The Aged) List: a\u00a0clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging 31:131\u2013140","journal-title":"Drugs Aging"},{"key":"2761_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/ageing\/afv077","volume":"44","author":"M Oelke","year":"2015","unstructured":"Oelke\u00a0M, Becher\u00a0K, Castro-Diaz\u00a0D et\u00a0al (2015) Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a\u00a0systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 44:745\u2013755","journal-title":"Age Ageing"},{"key":"2761_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1108\/09526860410557598","volume":"17","author":"RN Warburton","year":"2004","unstructured":"Warburton\u00a0RN, Parke\u00a0B, Church\u00a0W, McCusker\u00a0J (2004) Identification of seniors at risk: process evaluation of a\u00a0screening and referral program for patients aged \u3009 or = 75 in a\u00a0community hospital emergency department. Int J Health Care Qual Assur Inc Leadersh Health Serv 17:339\u2013348","journal-title":"Int J Health Care Qual Assur Inc Leadersh Health Serv"},{"key":"2761_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1553-2712.1998.tb02818.x","volume":"5","author":"J McCusker","year":"1998","unstructured":"McCusker\u00a0J, Bellavance\u00a0F, Cardin\u00a0S, Trepanier\u00a0S (1998) Screening for geriatric problems in the emergency department: reliability and validity. Identification of Seniors at Risk (ISAR) Steering Committee. Acad Emerg Med 5:883\u2013893","journal-title":"Acad Emerg Med"},{"key":"2761_CR13","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/j.1532-5415.1999.tb05204.x","volume":"47","author":"J McCusker","year":"1999","unstructured":"McCusker\u00a0J, Bellavance\u00a0F, Cardin\u00a0S, Trepanier\u00a0S, Verdon\u00a0J, Ardman\u00a0O (1999) Detection of older people at increased risk of adverse health outcomes after an emergency visit: the ISAR screening tool. J\u00a0Am Geriatr Soc 47:1229\u20131237","journal-title":"J Am Geriatr Soc"},{"key":"2761_CR14","first-page":"914","volume":"54","author":"S Iliffe","year":"2004","unstructured":"Iliffe\u00a0S, Lenihan\u00a0P, Orrell\u00a0M et\u00a0al (2004) The development of a\u00a0short instrument to identify common unmet needs in older people in general practice. Br J Gen Pract 54:914\u2013918","journal-title":"Br J Gen Pract"},{"key":"2761_CR15","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney\u00a0FI, Barthel\u00a0DW (1965) Functional evaluation: the Barthel index. Md State Med\u00a0J 14:61\u201365","journal-title":"Md State Med J"},{"key":"2761_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/21681805.2019.1570328","volume":"53","author":"MH Poulsen","year":"2019","unstructured":"Poulsen\u00a0MH, Frost\u00a0M, Abrahamsen\u00a0B, Gerke\u00a0O, Walter\u00a0S, Lund\u00a0L (2019) Osteoporosis and prostate cancer; a\u00a024-month prospective observational study during androgen deprivation therapy. Scand J Urol 53:34\u201339","journal-title":"Scand J Urol"},{"key":"2761_CR17","doi-asserted-by":"publisher","first-page":"39562","DOI":"10.1038\/srep39562","volume":"7","author":"SH Kim","year":"2017","unstructured":"Kim\u00a0SH, Joung\u00a0JY, Kim\u00a0S et\u00a0al (2017) Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: a\u00a012\u00a0month-prospective observational study. Sci Rep 7:39562","journal-title":"Sci Rep"},{"key":"2761_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/j.1464-410X.2011.10097.x","volume":"107","author":"ER Jefferies","year":"2011","unstructured":"Jefferies\u00a0ER, Thurairaja\u00a0R, Persad\u00a0RA, Rajani\u00a0R, Phull\u00a0JS, Bahl\u00a0A (2011) Don\u2019t think once, think twice! the cardiovascular effects of androgen deprivation therapy. BJU Int 107:1023\u20131028","journal-title":"BJU Int"},{"key":"2761_CR19","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith\u00a0MR, Saad\u00a0F, Chowdhury\u00a0S et\u00a0al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N\u00a0Engl J Med 378:1408\u20131418","journal-title":"N Engl J Med"},{"key":"2761_CR20","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain\u00a0M, Fizazi\u00a0K, Saad\u00a0F et\u00a0al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N\u00a0Engl J Med 378:2465\u20132474","journal-title":"N Engl J Med"},{"key":"2761_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer\u00a0TM, Armstrong\u00a0AJ, Rathkopf\u00a0DE et\u00a0al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N\u00a0Engl J Med 371:424\u2013433","journal-title":"N Engl J Med"},{"key":"2761_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi\u00a0K, Shore\u00a0N, Tammela\u00a0TL et\u00a0al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N\u00a0Engl J Med 380:1235\u20131246","journal-title":"N Engl J Med"},{"key":"2761_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo\u00a0D, Richardson\u00a0S (1991) The timed \u201cUp & Go\u201d: a\u00a0test of basic functional mobility for frail elderly persons. J\u00a0Am Geriatr Soc 39:142\u2013148","journal-title":"J Am Geriatr Soc"},{"key":"2761_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/geront\/gns071","volume":"53","author":"RE Rikli","year":"2013","unstructured":"Rikli\u00a0RE, Jones\u00a0CJ (2013) Development and validation of criterion-referenced clinically relevant fitness standards for maintaining physical independence in later years. Gerontologist 53:255\u2013267","journal-title":"Gerontologist"},{"key":"2761_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000475143","volume":"27","author":"The Italian Alfuzosin Cooperative Group","year":"1995","unstructured":"The Italian Alfuzosin Cooperative Group (1995) Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient\u2019s quality of life. Eur Urol 27:128\u2013134","journal-title":"Eur Urol"},{"key":"2761_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.prnil.2018.04.002","volume":"7","author":"A Ohtaka","year":"2019","unstructured":"Ohtaka\u00a0A, Aoki\u00a0H, Nagata\u00a0M et\u00a0al (2019) Sarcopenia is a\u00a0poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy. Prostate Int 7:9\u201314","journal-title":"Prostate Int"},{"key":"2761_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1754-9485.12124","volume":"58","author":"D Chang","year":"2014","unstructured":"Chang\u00a0D, Joseph\u00a0DJ, Ebert\u00a0MA et\u00a0al (2014) Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J\u00a0Med Imag Rad Onc 58:223\u2013228","journal-title":"J Med Imag Rad Onc"},{"key":"2761_CR28","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12885-018-4306-9","volume":"18","author":"JK Dawson","year":"2018","unstructured":"Dawson\u00a0JK, Dorff\u00a0TB, Schroeder\u00a0TE, Lane\u00a0CJ, Gross\u00a0ME, Dieli-Conwright\u00a0CM (2018) Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a\u00a0pilot randomized controlled trial. BMC Cancer 18:368","journal-title":"BMC Cancer"},{"key":"2761_CR29","doi-asserted-by":"publisher","first-page":"e016910","DOI":"10.1136\/bmjopen-2017-016910","volume":"7","author":"JL Kiwata","year":"2017","unstructured":"Kiwata\u00a0JL, Dorff\u00a0TB, Todd Schroeder\u00a0E et\u00a0al (2017) A\u00a0pilot randomised controlled trial of a\u00a0periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy. BMJ Open 7:e16910","journal-title":"BMJ Open"},{"key":"2761_CR30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/ggi.13163","volume":"18","author":"T Tanaka","year":"2018","unstructured":"Tanaka\u00a0T, Takahashi\u00a0K, Akishita\u00a0M, Tsuji\u00a0T, Iijima\u00a0K (2018) \u201cYubi-wakka\u201d (finger-ring) test: a\u00a0practical self-screening method for sarcopenia, and a\u00a0predictor of disability and mortality among Japanese community-dwelling older adults. Geriatr Gerontol Int 18:224\u2013232","journal-title":"Geriatr Gerontol Int"},{"key":"2761_CR31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4143\/crt.2018.119","volume":"51","author":"BS Tae","year":"2019","unstructured":"Tae\u00a0BS, Jeon\u00a0BJ, Shin\u00a0SH, Choi\u00a0H, Bae\u00a0JH, Park\u00a0JY (2019) Correlation of androgen deprivation therapy with cognitive dysfunction in patients with prostate cancer: a\u00a0nationwide population-based study using the national health insurance service database. Cancer Res Treat 51:593\u2013602","journal-title":"Cancer Res Treat"},{"key":"2761_CR32","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.urolonc.2012.07.003","volume":"31","author":"LM Wu","year":"2013","unstructured":"Wu\u00a0LM, Diefenbach\u00a0MA, Gordon\u00a0WA, Cantor\u00a0JB, Cherrier\u00a0MM (2013) Cognitive problems in patients on androgen deprivation therapy: a\u00a0qualitative pilot study. Urol Oncol 31:1533\u20131538","journal-title":"Urol Oncol"},{"key":"2761_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.socscimed.2016.03.016","volume":"156","author":"LM Wu","year":"2016","unstructured":"Wu\u00a0LM, Tanenbaum\u00a0ML, Dijkers\u00a0MP et\u00a0al (2016) Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: a\u00a0mixed methods study. Soc Sci Med 156:80\u201389","journal-title":"Soc Sci Med"},{"key":"2761_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/ajco.12347","volume":"11","author":"J Yang","year":"2015","unstructured":"Yang\u00a0J, Zhong\u00a0F, Qiu\u00a0J, Wang\u00a0K (2015) Cognitive function in Chinese prostate cancer patients on androgen-deprivation therapy: a\u00a0cross-sectional study. Asia Pac J Clin Oncol 11:277\u2013281","journal-title":"Asia Pac J Clin Oncol"},{"key":"2761_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/jamaoncol.2016.3662","volume":"3","author":"KT Nead","year":"2017","unstructured":"Nead\u00a0KT, Gaskin\u00a0G, Chester\u00a0C, Swisher-McClure\u00a0S, Leeper\u00a0NJ, Shah\u00a0NH (2017) Association between androgen deprivation therapy and risk of dementia. JAMA Oncol 3:49\u201355","journal-title":"JAMA Oncol"},{"key":"2761_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/1471-2407-12-371","volume":"12","author":"HH Chao","year":"2012","unstructured":"Chao\u00a0HH, Uchio\u00a0E, Zhang\u00a0S et\u00a0al (2012) Effects of androgen deprivation on brain function in prostate cancer patients\u2014a\u00a0prospective observational cohort analysis. BMC Cancer 12:371","journal-title":"BMC Cancer"},{"key":"2761_CR37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41391-018-0037-x","volume":"21","author":"MM Cherrier","year":"2018","unstructured":"Cherrier\u00a0MM, Cross\u00a0DJ, Higano\u00a0CS, Minoshima\u00a0S (2018) Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer. Prostate Cancer Prostatic Dis 21:394\u2013402","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2761_CR38","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","volume":"5","author":"AM Moilanen","year":"2015","unstructured":"Moilanen\u00a0AM, Riikonen\u00a0R, Oksala\u00a0R et\u00a0al (2015) Discovery of ODM-201, a\u00a0new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 5:12007","journal-title":"Sci Rep"},{"key":"2761_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","volume":"18","author":"SCR Williams","year":"2023","unstructured":"Williams\u00a0SCR, Mazibuko\u00a0N, O\u2019Daly\u00a0O et\u00a0al (2023) Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a\u00a0randomized crossover trial. Target Oncol 18:403\u2013413","journal-title":"Target Oncol"},{"key":"2761_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein\u00a0MF, Folstein\u00a0SE, McHugh\u00a0PR (1975) \u201cMini-mental state\u201d. A\u00a0practical method for grading the cognitive state of patients for the clinician. J\u00a0Psychiatr Res 12:189\u2013198","journal-title":"J Psychiatr Res"},{"key":"2761_CR41","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/1099-1166(200006)15:6<548::AID-GPS242>3.0.CO;2-U","volume":"15","author":"KI Shulman","year":"2000","unstructured":"Shulman\u00a0KI (2000) Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15:548\u2013561","journal-title":"Int J Geriatr Psychiatry"},{"key":"2761_CR42","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.1532-5415.1989.tb02233.x","volume":"37","author":"T Sunderland","year":"1989","unstructured":"Sunderland\u00a0T, Hill\u00a0JL, Mellow\u00a0AM et\u00a0al (1989) Clock drawing in Alzheimer\u2019s disease. A\u00a0novel measure of dementia severity. J\u00a0Am Geriatr Soc 37:725\u2013729","journal-title":"J Am Geriatr Soc"},{"key":"2761_CR43","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/j.1532-5415.1993.tb07308.x","volume":"41","author":"YI Watson","year":"1993","unstructured":"Watson\u00a0YI, Arfken\u00a0CL, Birge\u00a0SJ (1993) Clock completion: an objective screening test for dementia. J\u00a0Am Geriatr Soc 41:1235\u20131240","journal-title":"J Am Geriatr Soc"},{"key":"2761_CR44","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.acuro.2015.01.004","volume":"39","author":"JI Monzo-Gardiner","year":"2015","unstructured":"Monzo-Gardiner\u00a0JI, Herranz-Amo\u00a0F (2015) Cardiovascular mortality in patients with prostate cancer exposed to androgen deprivation therapy. Actas Urol Esp 39:518\u2013522","journal-title":"Actas Urol Esp"},{"key":"2761_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1756287215617872","volume":"8","author":"P Zareba","year":"2016","unstructured":"Zareba\u00a0P, Duivenvoorden\u00a0W, Leong\u00a0DP, Pinthus\u00a0JH (2016) Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol 8:118\u2013129","journal-title":"Ther Adv Urol"},{"key":"2761_CR46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/jcph.1332","volume":"59","author":"HH Kao","year":"2019","unstructured":"Kao\u00a0HH, Kao\u00a0LT, Li\u00a0IH et\u00a0al (2019) Androgen deprivation therapy use increases the risk of heart failure in patients with prostate cancer: a\u00a0population-based cohort study. J\u00a0Clin Pharmacol 59:335\u2013343","journal-title":"J Clin Pharmacol"},{"key":"2761_CR47","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2020.05.09","author":"D Margel","year":"2019","unstructured":"Margel\u00a0D, Peer\u00a0A, Ber\u00a0Y et\u00a0al (2019) Cardiovascular morbidity in a\u00a0randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J\u00a0Urol. https:\/\/doi.org\/10.1590\/s1677-5538.ibju.2020.05.09","journal-title":"J Urol"},{"key":"2761_CR48","doi-asserted-by":"publisher","first-page":"695170","DOI":"10.3389\/fendo.2021.695170","volume":"12","author":"A Sciarra","year":"2021","unstructured":"Sciarra\u00a0A, Busetto\u00a0GM, Salciccia\u00a0S et\u00a0al (2021) Does exist a\u00a0differential impact of degarelix versus LHRH agonists on cardiovascular safety? Evidences from randomized and real-world studies. Front Endocrinol 12:695170","journal-title":"Front Endocrinol"},{"key":"2761_CR49","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00120-015-0013-1","volume":"55","author":"AS Merseburger","year":"2016","unstructured":"Merseburger\u00a0AS, Sedding\u00a0D, Huter\u00a0K (2016) Cardiovascular risk patients under androgen deprivation therapy: lower risk with GnRH antagonists compared to LHRH agonists? Urologe\u00a0A 55:218\u2013225","journal-title":"Urologe A"},{"key":"2761_CR50","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/EDE.0000000000000678","volume":"28","author":"BM Hicks","year":"2017","unstructured":"Hicks\u00a0BM, Klil-Drori\u00a0AJ, Yin\u00a0H, Campeau\u00a0L, Azoulay\u00a0L (2017) Androgen deprivation therapy and the risk of anemia in men with prostate cancer. Epidemiology 28:712\u2013718","journal-title":"Epidemiology"},{"key":"2761_CR51","first-page":"3877","volume":"10","author":"D Dai","year":"2018","unstructured":"Dai\u00a0D, Han\u00a0S, Li\u00a0L et\u00a0al (2018) Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a\u00a0systematic review and meta-analysis. Am J Transl Res 10:3877\u20133886","journal-title":"Am J Transl Res"},{"key":"2761_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.02.002","author":"KH Tully","year":"2019","unstructured":"Tully\u00a0KH, Nguyen\u00a0DD, Herzog\u00a0P et\u00a0al (2019) Risk of dementia and depression in young and middle-aged men presenting with nonmetastatic prostate cancer treated with androgen deprivation therapy. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2020.02.002","journal-title":"Eur Urol Oncol"},{"key":"2761_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/13685538.2019.1586869","author":"Y Ceylan","year":"2019","unstructured":"Ceylan\u00a0Y, Gunlusoy\u00a0B, Koskderelioglu\u00a0A, Gedizlioglu\u00a0M, Degirmenci\u00a0T (2019) The depressive effects of androgen deprivation therapy in locally advanced or metastatic prostate cancer: a\u00a0comparative study. Aging Male. https:\/\/doi.org\/10.1080\/13685538.2019.1586869","journal-title":"Aging Male"},{"key":"2761_CR54","first-page":"1160","volume":"36","author":"JI Sheikh","year":"1985","unstructured":"Sheikh\u00a0JI, Yesavage\u00a0JA (1985) A\u00a0knowledge assessment test for geriatric psychiatry. Hosp Community Psychiatry 36:1160\u20131166","journal-title":"Hosp Community Psychiatry"},{"key":"2761_CR55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1017\/S1041610291000480","volume":"3","author":"JI Sheikh","year":"1991","unstructured":"Sheikh\u00a0JI, Yesavage\u00a0JA, Brooks\u00a0JO 3rd et\u00a0al (1991) Proposed factor structure of the geriatric depression scale. Int Psychogeriatr 3:23\u201328","journal-title":"Int Psychogeriatr"},{"key":"2761_CR56","first-page":"369","volume":"39","author":"JI Sheikh","year":"1988","unstructured":"Sheikh\u00a0JI, Yesavage\u00a0JA, Gulevich\u00a0G (1988) Validation of the geriatric psychiatry knowledge test. Hosp Community Psychiatry 39:369\u2013375","journal-title":"Hosp Community Psychiatry"},{"key":"2761_CR57","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jad.2014.11.012","volume":"173","author":"SD Ostergaard","year":"2015","unstructured":"Ostergaard\u00a0SD, Pedersen\u00a0CH, Uggerby\u00a0P et\u00a0al (2015) Clinical and psychometric validation of the psychotic depression assessment scale. J\u00a0Affect Disord 173:261\u2013268","journal-title":"J Affect Disord"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02761-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02761-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02761-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:03:27Z","timestamp":1770822207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02761-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2761"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02761-9","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Siehe Tab.\u00a0\n                      \n                      im Anhang.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}